This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Molecular regulation

Authoring team

Cellular proliferation and differentiation is a balance of elements which tend to enhance or retard each function. Growth factors have their signal transduced at the nucleus into a complex web of activation of two types of gene:

  • proto-oncogenes:
    • normal cellular genes which may be switched on in an abnormal manner or may produce too much of their gene product, so stimulating excessive cellular proliferation - they become oncogenes
    • act via tyrosine kinase production, and hence protein phosphorylation, G protein or nuclear protein production
    • can be activated by point mutations, translocations of regions of chromosomes, or duplication and hence excessive production of the proto-oncogene
    • an example of an oncogene is ras which is derived from a proto-oncogene by a point mutation and is implicated in a variety of human cancers
  • tumour suppressor genes:
    • normal cellular genes hypothesised to switch off or suppress cellular proliferation
    • the inactivation or under-expression of such genes could stimulate over-proliferation of cells
    • may be disrupted by the same molecular mechanisms as those affecting proto-oncogenes, e.g. point mutation
    • an example of a tumour suppressor gene is p53 which is variably mutated in its associations with human liver, lung, stomach, colon and breast cancer

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.